ClinicalTrials.gg
SuspendedNCT07283900AIMSUpdated Oct 9, 2026

Ascorbate in Myelodysplastic Syndrome

A Phase 2 interventional study of High-dose ascorbate and Azacitidine in Myelodysplastic Syndromes, sponsored by Prajwal Dhakal. Suspended at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Prajwal Dhakal · Phase 2, Interventional, and Treatment

How we know

Why this study was suspended
temporary suspension
Updated Oct 9, 2026Now SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing Ascorbic Acid in Myelodysplastic Syndromes — 1 open to participants now, 2 under way, none of them phase 3. Ascorbic Acid · Myelodysplastic Syndromes.

Planned enrollment
4th of 10
38 · median 23
Started
2026
the only one that year
Phase 2
7 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Prajwal Dhakal

Among the 10 studies testing Ascorbic Acid in Myelodysplastic Syndromes, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 7 in phase 2, and was the 10th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

1 of the 10 studies testing Ascorbic Acid in Myelodysplastic Syndromes is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Ascorbic Acid

Ascorbic Acid: first FDA approval 1947 (BEROCCA PN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Ascorbic Acid in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.

Read the detailed description

This Phase II clinical trial investigates the combination of high-dose intravenous ascorbate (vitamin C) with azacitidine in adults with higher-risk myelodysplastic syndrome (MDS). The study includes a small safety run-in followed by an efficacy phase, enrolling a total of 38 participants. It aims to determine whether adding high-dose ascorbate can safely enhance the therapeutic response to azacitidine, a standard hypomethylating agent used in MDS treatment.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Vitamin C
  • Ascorbate
  • Myelodysplastic Syndrome
  • AIMS
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Diagnosis of myelodysplastic syndrome (MDS) requiring treatment with a hypomethylating agent (HMA).
  • Higher-risk MDS per the Molecular International Prognostic Scoring System (IPSS-M) - Moderate High, High, or Very High risk categories.
  • No prior MDS-directed therapy, except:

    ≤ 1 prior cycle of azacitidine, decitabine, or oral decitabine-cedazuridine; or prior use of ESA, luspatercept, or imetelstat. Prior hydroxyurea use is allowed but continuation beyond Cycle 1 requires PI approval.

  • performance status 0-2.
  • Adequate organ function: >45 mL/min; total ≤1.5 × ; and AST ≤3 × ULN.
  • Ability to provide written .
  • Willingness to comply with study visits, treatment, and requirements.
  • Negative pregnancy test for women of at screening.

Exclusion criteria

Exclusion Criteria

  • MDS with isolated del(5q) eligible for lenalidomide therapy.
  • MDS/MPN overlap syndromes other than MDS.
  • Known or allergy to ascorbate or azacitidine.
  • Pregnant or nursing individuals.
  • Inability or unwillingness to use adequate .
  • Uncontrolled intercurrent illness including active infection, recent myocardial infarction (≤6 months), uncontrolled heart failure or arrhythmia, pulmonary edema, unstable angina, or significant psychiatric illness.
  • Renal disease requiring dialysis, diabetic nephropathy, renal transplant recipients, or history of oxalate nephropathy.
  • Paroxysmal nocturnal hemoglobinuria.
  • Uncontrolled infection (patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible).
  • G6PD deficiency.
  • Use of warfarin (due to potential interaction with high-dose ascorbate).
  • Diabetic patients using fingerstick or continuous glucose monitors to adjust insulin doses (ascorbate can cause false readings).
  • Concurrent active , except adequately treated nonmelanoma skin cancer or curatively treated in situ cancers with >2 years disease-free.
  • Systemic therapy with prednisone ≥20 mg/day (or equivalent), except for inhaled or topical .
  • Primary hemochromatosis or transfusion-related iron overload (ferritin >1000 ng/mL).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    High-Dose Ascorbate + Azacitidine

    All participants receive the combination of high-dose intravenous ascorbate (75 g on days 1, 3, 5, and 7) and azacitidine (75 mg/m² intravenous or subcutaneous on days 1-7) in 28-day treatment cycles.

    Drug: High-dose ascorbate · Drug: Azacitidine

Interventions

  • DrugAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ascorbate, or vitamin C, is a water-soluble vitamin with antioxidant properties that also functions as a cofactor for several enzymatic reactions, including collagen synthesis and the activity of dioxygenase enzymes involved in DNA and histone demethylation

    Also known as: Vitamin C

  • Azacitidine is a pyrimidine nucleoside analog of cytidine that incorporates into RNA and DNA, inhibiting DNA methyltransferase and leading to global DNA hypomethylation

    Also known as: Vidaza

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Assess the safety and tolerability of intravenous (IV) high-dose ascorbate (HDA) in combination with azacitidine.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Treatment Efficacy

    Proportion of participants achieving a complete response (CR) or partial response (PR)

    Time frame: At the end of Cycle 4 (each cycle is 28 days)

Secondary outcomes

  1. Overall Survival (OS)

    Time from treatment initiation to death from any cause.

    Time frame: From treatment initiation until death from any cause or up to 24 months, whichever comes first

  2. Event-Free Survival (EFS)

    Time from treatment initiation to progression, relapse, treatment failure, or death.

    Time frame: From treatment initiation until disease progression, disease relapse, treatment failure, or death from any cause, whichever came first, assessed up to 24 months

  3. Transfusion Requirements

    Changes in red blood cell and platelet transfusion needs during treatment.

    Time frame: At baseline, assessed throughout the treatment up to the end of cycle 4 (each cycle is 28 days)

  4. Hematologic Parameters

    Changes in hemoglobin, platelet, and neutrophil counts.

    Time frame: At baseline, assessed throughout the treatment up to the end of cycle 4 (each cycle is 28 days)

  5. Composite Complete Response (cCR) Rate

    Proportion of participants achieving CR, CRh, CRL, or CR-equivalent per IWG 2023 criteria.

    Time frame: At the end of cycle 4 (each cycle is 28 days)

  6. Overall Response Rate (ORR)

    Proportion of participants achieving CR, CRh, CRL, PR, or hematologic improvement (HI) per IWG 2023 criteria after four treatment cycles

    Time frame: At the end of cycle 4 (each cycle is 28 days)

  7. Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    HRQOL will be assessed using the EORTC QLQ-C30 questionnaire. This outcome measure will evaluate participants' overall quality of life, functional status, and symptom burden at various time points throughout the study. Scoring Range: 0 to 100 for each scale. Functioning Scales: Higher scores = better functioning. Symptom Scales: Higher scores = worse symptoms. Global Health Status/QOL Scale: Higher scores = better overall QOL.

    Time frame: At baseline, at the end of cycle 4, every 3 months after the end of cycle 4 up to 24 months (each cycle is 28 days)

  8. Health-Related Quality of Life (HRQOL) using EuroQol (EQ-5D-5L) questionnaire

    HRQOL will be assessed using the EQ-5D-5L questionnaire, which uses a descriptive system and a visual analogue scale. The descriptive system will evaluate participants' mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scoring range: 11111 to 55555. Higher scores= worse problems. The visual analog scale asks patients to rate their current health on a scale of 0 to 100. Higher scores= better health status.

    Time frame: At baseline, at the end of cycle 4, every 3 month after end of cycle 4 up to 24 months (each cycle is 28 days)

07

Study locations

1 site
  • University of Iowa
    Iowa City, Iowa 52242, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 16, 2025
StartActual
Mar 11, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended temporary suspension
changed Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Suspended
    Why stopped temporary suspension
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07283900
Lead sponsor
Prajwal Dhakal
Responsible party
Prajwal Dhakal (Clinical Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Dec 16, 2025
Start date
Mar 11, 2026
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Prajwal Dhakal, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ascorbic Acid · Azacitidine

Start the discussion